

PHARMACEUTICAL 2023

Repare Therapeutics Inc. Rank 97 of 446









RealRate

PHARMACEUTICAL 2023





The relative strengths and weaknesses of Repare Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Repare Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Repare Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 201%, being 158% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	353,979
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	78,619
Liabilities, Non-Current	5,939
Other Assets	5,868
Other Compr. Net Income	-428
Other Expenses	15,147
Other Liabilities	0
Other Net Income	137,726
Other Revenues	0
Property and Equipment	4,228
Research and Development	119,066
Selling, General and Administrative Expense	32,560

Output Variable	Value in 1000 USD
Assets	364,075
Liabilities	84,558
Expenses	166,773
Revenues	0
Stockholders Equity	279,517
Net Income	-29,047
Comprehensive Net Income	-29,261
Economic Capital Ratio	201%

